Rare Disease Advisor

  • Home
  • Rare Disease Advisor

Rare Disease Advisor Trusted knowledge base of resources & information, focused on treating & diagnosing .

Rare Disease Advisor is an online resource that provides health care professionals with comprehensive information on important principles of care in rare diseases as well as up-to-date clinical news on the diagnosis and treatment of these conditions. Website features include:

• Daily news
• Feature articles on key issues in rare disease
• Live conference coverage
• Expert opinion articles, includ

ing exclusive guest editorials from leading rare disease experts
• Concise drug monographs
• Medical slideshows
• Videos
• Continuing medical education (CME) activities
• And more...


Coverage of the following Rare Diseases:

Cardiology:
Long Chain Fatty Acid Oxidation Disorder (LCFAOD)
Pompe Disease

Gastroenterology:
Gastrointestinal Stromal Tumor (GIST)

Hematology:
Hemophilia
Sickle Cell Disease (SCD)
Systemic Mastocytosis (SM)

Hepatology:
Alagille Syndrome (ALGS)
Lysosomal Acid Lipase Deficiency (LAL-D)

Immunology:
Cold Agglutinin Disease (CAD or CAgD)
Hereditary Angioedema (HAE)
Myasthenia Gravis (MG)

Neurology:
Duchenne Muscular Dystrophy (DMD)
Multiple Sclerosis (MS)
Spinal Muscular Atrophy (SMA)
Hereditary Transthyretin Amyloidosis (hATTR)
Neuromyelitis Optica Spectrum Disorder (NMOSD)

Oncology:
Cholangiocarcinoma (CCA)
Medullary Thyroid Carcinoma (MTC)
Diffuse Large B-Cell Lymphoma (DLBCL)

Pulmonology:
Alpha-1 Antitrypsin Deficiency (AATD)
Cystic Fibrosis (CF)
Idiopathic Pulmonary Fibrosis (IPF)
Pulmonary Arterial Hypertension (PAH)

An unusual case involving a patient with sickle cell anemia, raises the possibility that SCA may act as a secondary caus...
03/01/2025

An unusual case involving a patient with sickle cell anemia, raises the possibility that SCA may act as a secondary cause of immune thrombocytopenia.

The case report, published in Cureus, Inc., ruled out other possible causes of ITP, leading to the conclusion that the immune dysregulation of SCA itself might have been the underlying cause.

The patient was a 20-year-old man with SCA who presented with thrombocytopenia and chest and lower limb pain, which were suggestive of a vaso-occlusive crisis. He had no signs of , no fever or neurological deficits, and no history of recent trauma.

Read more: https://bit.ly/4j2GC1X

Researchers describe an unusual case of sickle cell disease (SCD) as a potential secondary cause of immune thrombocytopenia (ITP).

Deep prenatal phenotyping is crucial for diagnosing fetal genetic disorders and abnormalities, including fetal and neona...
03/01/2025

Deep prenatal phenotyping is crucial for diagnosing fetal genetic disorders and abnormalities, including fetal and neonatal alloimmune thrombocytopenia ( ), according to a recent review in Best Practice & Research: Clinical Obstetrics & Gynaecology.

Read more: https://www.rarediseaseadvisor.com/news/fetal-deep-phenotyping-may-help-diagnose-fnait-other-fetal-diseases/

Fetal imaging is becoming more essential for selecting the most relevant diagnostic tests regarding anticipated perinatal prognosis.

Researchers have identified a key subpopulation of dividing cells in chronic lymphocytic leukemia that may drive disease...
03/01/2025

Researchers have identified a key subpopulation of dividing cells in chronic lymphocytic leukemia that may drive disease progression and impact clinical outcomes, according to a study in HemaSphere.

Read more: https://bit.ly/400bwQ7

Researchers identified a critical subpopulation of CLL dividing cells that could drive disease progression and influence clinical outcomes.

👋 Meet Faye Adams!At just 44 years old, Faye was diagnosed with ATTR-CM, defying expectations for her gene mutation. Now...
02/01/2025

👋 Meet Faye Adams!

At just 44 years old, Faye was diagnosed with ATTR-CM, defying expectations for her gene mutation. Now, she’s on a mission to raise awareness, challenge misconceptions, and educate others about amyloidosis.

“The word “amyloidosis” has been a part of my life since 2009. Initially, I encountered it as a caregiver to my dad, who ultimately passed away in 2010. The term resurfaced in 2020 when I was diagnosed at the age of 44, and I still find myself confused.

I’ve made it my mission to raise awareness about this disease. I want to put a face to amyloidosis because I break the mold. I am female, and I was 44 at the time of my diagnosis, which is considered young for my particular gene mutation. However, one thing about gene mutations is that they don’t always follow a predictable pattern.
I am Faye, and I am living, fighting, and educating doctors, patients, and caregivers about ATTR-CM.”

Read more from Faye here: https://bit.ly/4j2chRq

  can be effective for reducing   frequency over a long-term period in patients with developmental and epileptic encepha...
02/01/2025

can be effective for reducing frequency over a long-term period in patients with developmental and epileptic encephalopathies such as Lennox-Gastaut syndrome and Dravet syndrome according to a study in Scientific Reports.

After 60 months of treatment with perampanel, the rates of patients who experienced a greater than 50% reduction in seizure frequency were 33.3% for atypical absence seizures, 33.3% for tonic seizures, 38.5% for focal seizures, 54.5% for generalized tonic-clonic seizures, 54.5% for myoclonic seizures, and 36.4% for atonic seizures.

Read more: https://bit.ly/40fe3qK

Perampanel is effective for long-term seizure reduction in patients with developmental and epileptic encephalopathies, like LGS and DS, a study found.

✅ Japanese individuals with generalized pustular psoriasis, plaque psoriasis, and erythrodermic psoriasis experienced im...
02/01/2025

✅ Japanese individuals with generalized pustular psoriasis, plaque psoriasis, and erythrodermic psoriasis experienced improvements in symptoms and quality of life with 6 mg of .

The results revealed that patients in all 3 psoriasis groups reported meaningful improvements in signs, symptoms, and quality of life scores with deucravacitinib therapy, with two-thirds of all patients reporting that their QoL was not impacted by their disease after 52 weeks.

Read more: https://www.rarediseaseadvisor.com/news/japanese-patients-gpp-report-improvements-deucravacitinib/

Japanese patients with generalized pustular psoriasis (GPP) report improvements after 52 weeks of deucravacitinib therapy.

🥇 Our most-read and shared article of the year focused on a critical topic:   for   and the complexities surrounding its...
30/12/2024

🥇 Our most-read and shared article of the year focused on a critical topic: for and the complexities surrounding its implementation.

The recent approval of multiple gene therapies has sparked a renewed push for newborn screening, but significant challenges remain. Screening varies widely across states, and the process is often misunderstood. Of the 4 million babies born annually in the U.S., approximately 12,500 (nearly 1 in 300) are diagnosed with one of the core conditions included in newborn screening programs.

🔗 Read the most popular story of 2024 here: https://www.rarediseaseadvisor.com/reports/new-gene-therapies-win-approval-newborn-screening-programs-proliferate/

A study published in Medicina (MDPI) found that patients with hereditary transthyretin amyloid polyneuropathy (ATTR-PN) ...
30/12/2024

A study published in Medicina (MDPI) found that patients with hereditary transthyretin amyloid polyneuropathy (ATTR-PN) displayed similar electroneurographic findings to those with light-chain amyloidosis but experienced faster clinical progression.

Both groups of patients showed decreased motor and sensory amplitudes over a 24-month period but the patients with ATTR-PN also displayed decreased muscle strength with changes in their polyneuropathy disability scale stage.

Read more: https://bit.ly/41RXkuW

Patients with light-chain amyloidosis and ATTR-PN show similar nerve impairment but different clinical progression over time, a study found.

ATLAS 2030, the medical lower-body exoskeleton for children is safe for patients with spinal muscular atrophy and cerebr...
30/12/2024

ATLAS 2030, the medical lower-body exoskeleton for children is safe for patients with spinal muscular atrophy and cerebral palsy. Satisfaction of the therapists was also high with the device.

Read more: https://bit.ly/4iPEZox

A medical lower-body exoskeleton for children is safe for patients with spinal muscular atrophy (SMA) and cerebral palsy (CP), a study found.

💡 2024 Rare Disease Highlights Countdown:  #2 This year, artificial intelligence emerged as a game-changer in   and trea...
29/12/2024

💡 2024 Rare Disease Highlights Countdown: #2

This year, artificial intelligence emerged as a game-changer in and treatment. The FDA has received hundreds of applications incorporating AI or machine learning into drug development, signaling a transformative shift in how therapies are designed and tested.

AI’s unparalleled potential offers new hope for the rare disease community, where limited patient populations and complex conditions often pose significant challenges.

🔗 Read the full story: https://bit.ly/4fyy4NC

The US Food and Drug Administration has received hundreds of applications incorporating AI or machine learning in drug development.

🌟 Rare Disease Highlights Countdown:  #32024 marked a major win for rare disease advocacy! On September 23, 2024, the US...
28/12/2024

🌟 Rare Disease Highlights Countdown: #3

2024 marked a major win for rare disease advocacy! On September 23, 2024, the US House of Representatives unanimously passed the Give Kids a Chance Act, extending the Rare Pediatric Disease Priority Review Voucher program until 2029.

The RPD PRV program incentivizes pharmaceutical companies to develop novel therapies for rare pediatric diseases by offering priority review vouchers from the FDA, reducing application review times from 10 months to just 6 months.

This victory wouldn’t have been possible without the tireless efforts of advocacy groups like National Organization for Rare Disorders, Inc. (NORD), the Muscular Dystrophy Association, and many other nonprofits working to improve outcomes for children with rare diseases.

🔗 Read the full story: https://bit.ly/3DGMjT0.

🔎 2024 Rare Disease Highlights Countdown:  #4In the complex world of chronic inflammatory demyelinating polyneuropathy (...
27/12/2024

🔎 2024 Rare Disease Highlights Countdown: #4

In the complex world of chronic inflammatory demyelinating polyneuropathy ( ), misdiagnosis remains a significant challenge with serious implications for patients.

Research reveals that more than half of CIDP patients are initially misdiagnosed, delaying proper treatment. Even more troubling, nearly half of those diagnosed with CIDP don’t actually have the condition, potentially exposing them to unnecessary treatments and missed opportunities for accurate care.

🔗 Read the full story: https://bit.ly/4gvz8D8

A study published in Medicina found that patients with hereditary transthyretin amyloid polyneuropathy (ATTR-PN) exhibit...
27/12/2024

A study published in Medicina found that patients with hereditary transthyretin amyloid polyneuropathy (ATTR-PN) exhibit electroneurographic findings similar to those seen in light-chain amyloidosis patients, though ATTR-PN progresses more rapidly clinically.

Read more: https://bit.ly/41RXkuW

Patients with light-chain amyloidosis and ATTR-PN show similar nerve impairment but different clinical progression over time, a study found.

2024 Rare Disease Highlights Countdown:  #5Huntington disease (HD) is often compared to having Parkinson’s, Alzheimer’s,...
26/12/2024

2024 Rare Disease Highlights Countdown: #5

Huntington disease (HD) is often compared to having Parkinson’s, Alzheimer’s, and ALS all at once—a degenerative and ultimately fatal illness that profoundly impacts patients and their families. With symptoms such as uncontrollable movements, mood swings, and slurred speech, and with no cure in sight, treatment options remain limited.

In the search for relief, some HD patients are turning to cannabis as a nonpharmaceutical alternative. According to Dr. Jordan Tishler, founder of the Association of Cannabinoid Specialists and InhaleMD, cannabis can help alleviate symptoms like pain, muscle spasms, and sleep disturbances when carefully tailored to individual needs.

🔗 Read the full story: https://bit.ly/4gx7B49

What are your thoughts on using cannabis for rare disease symptom management?

Among patients with  , the use of repeated   has been shown to be a safe and effective treatment for episodes of recurre...
26/12/2024

Among patients with , the use of repeated has been shown to be a safe and effective treatment for episodes of recurrent bleeding.

Read more: https://bit.ly/3VSppys

The use of repeated radiosynovectomy (RS) may be a safe and effective treatment for episodes of recurrent bleeding in patients with hemophilia.

Dr. Dimitrios Karussis, a Greek neurologist, and his team have made strides in using stem cells to stop Multiple Scleros...
25/12/2024

Dr. Dimitrios Karussis, a Greek neurologist, and his team have made strides in using stem cells to stop Multiple Sclerosis in its tracks.

In 2020, Dr. Karussis led a phase 2 study involving 48 patients with secondary progressive multiple sclerosis (SPMS). The patients were divided into three groups: one received a placebo, one received stem cells from their own bone marrow injected intravenously, and the third received stem cells injected directly into their cerebrospinal fluid. The results were encouraging, with the third group showing significant improvements in motor function and disease stabilization.

Building on these promising findings, Dr. Karussis planned a phase 2b trial involving 80 patients across Israel and the U.S., with participation from major institutions like Massachusetts General Hospital, University of Miami, and Mount Sinai Hospital.

🔗 Read the full story: https://www.rarediseaseadvisor.com/features/stem-cell-research-israel-could-lead-breakthroughs-treating-ms/

25/12/2024

🌟✨ Wishing a season of warmth, joy, and hope to our amazing community of rare disease patients, healthcare professionals, and their families. Your strength and resilience light up our world. May your holidays be filled with moments of connection, understanding, and well-deserved joy. Happy Holidays from Rare Disease Advisor! 🎄❤️

🔎  The 2024 Rare Disease Highlights Countdown continues!The impact of COVID-19 continues to shape our understanding of r...
24/12/2024

🔎 The 2024 Rare Disease Highlights Countdown continues!

The impact of COVID-19 continues to shape our understanding of rare diseases. A recent study explored the potential link between COVID-19 infection and the development of neuromuscular disorders like chronic inflammatory demyelinating polyneuropathy ( ).

Researchers focused on patients who experienced weakness or paresthesia following a COVID-19 infection. Using advanced diagnostics such as nerve conduction studies and needle electromyography, they aimed to better characterize this connection and its implications for care.

🔗 Read the full story: https://bit.ly/4095vS8

Address


Alerts

Be the first to know and let us send you an email when Rare Disease Advisor posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Rare Disease Advisor:

Videos

Shortcuts

  • Address
  • Alerts
  • Contact The Business
  • Videos
  • Claim ownership or report listing
  • Want your business to be the top-listed Media Company?

Share